Companies TCR2 Therapeutics Inc
TCR2 Therapeutics (TCRR): executive pay, fiscal 2022
Free brief. Every figure links to the company’s own filing.
TCR2 Therapeutics Inc no longer files a proxy statement; its last pay data is FY2022.
CEO pay, last three years
- $1,904,534FY2021
- $1,744,815FY2022
CEO total pay was $1,744,815 in fiscal 2022, down from $1,904,534 in fiscal 2021.
FY2022: salary $602,800 · bonus $0 · stock awards $666,160 · option awards $154,705
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Garry Menzel | $602,800 | $0 | $666,160 | $154,705 | $312,000 | $0 | $9,150 | $1,744,815 |
| President and Chief Executive Officer | ||||||||
| Rosemary Harrison | 372,083 | 0 | 12,437 | 531,582 | 140,000 | 0 | 10,461 | 1,066,563 |
| Chief Business & Strategy Officer | ||||||||
| Alfonso Cardama | 486,000 | 5,000 | 281,037 | 45,922 | 183,000 | 0 | 11,150 | 1,012,109 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| Garry Menzel | $1,744,815 | $1,904,534 | — | ↓ −159,719 |
| Rosemary Harrison | 1,066,563 | — | — | — |
| Alfonso Cardama | 1,012,109 | 1,039,084 | — | ↓ −26,975 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2022
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Alfonso Cardama | RSU | 11,775 | — | $11,775 |
| Rosemary Harrison | RSU | 12,882 | — | 12,882 |
| Alfonso Cardama | RSU | 17,447 | — | 17,447 |
| Garry Menzel | RSU | 39,681 | — | 39,681 |
| Garry Menzel | RSU | 41,526 | — | 41,526 |
| Rosemary Harrison | PSU | 46,597 | — | 46,597 |
| Alfonso Cardama | PSU | 57,350 | — | 57,350 |
| Alfonso Cardama | Option | 70,649 | 0.97 | — |
| Rosemary Harrison | Option | 76,930 | 0.97 | — |
| Alfonso Cardama | Option | 114,700 | 5.21 | — |
| Garry Menzel | PSU | 152,900 | — | 152,900 |
| Rosemary Harrison | Option | 191,102 | 4.04 | — |
| Garry Menzel | Option | 238,008 | 0.97 | — |
| Garry Menzel | Option | 305,800 | 5.21 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Stephen WebsterIndependent | $85,000 | — | $10,920 | — | $0 | $95,920 |
| Neil W. GibsonIndependent | 57,500 | — | 10,920 | — | 0 | 68,420 |
| Andrew AllenIndependent | 52,500 | — | 10,920 | — | 0 | 63,420 |
| Shawn TomaselloIndependent | 49,000 | — | 10,920 | — | 0 | 59,920 |
| Priti HegdeIndependent | 44,000 | — | 10,920 | — | 0 | 54,920 |
| Axel HoosIndependent | 44,000 | — | 10,920 | — | 0 | 54,920 |
| Ansbert GadickeNot independent | 0 | — | 0 | — | 0 | — |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $332,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $332,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names TCR2 Therapeutics as a peer
Companies that benchmark against TCRR
No companies currently name TCRR as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TCR2 Therapeutics Inc | 2022 | Garry Menzel | $602,800 | $666,160 | $154,705 | $312,000 | $1,744,815 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (13 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Garry Menzel. 10-K, filed 2023-03-23. Section “Executive Compensation” · page 141. As printed: 1,744,815. View filing ↗
- Section 01, Rosemary Harrison. 10-K, filed 2023-03-23. Section “Executive Compensation” · page 141. As printed: 1,066,563. View filing ↗
- Section 01, Alfonso Cardama. 10-K, filed 2023-03-23. Section “Executive Compensation” · page 141. As printed: 1,012,109. View filing ↗
- Section 08, Stephen Webster. 10-K, filed 2023-03-23. Section “Director Compensation”. As printed: 95,920. View filing ↗
- Section 08, Neil W. Gibson. 10-K, filed 2023-03-23. Section “Director Compensation”. As printed: 68,420. View filing ↗
- Section 08, Andrew Allen. 10-K, filed 2023-03-23. Section “Director Compensation”. As printed: 63,420. View filing ↗
- Section 08, Shawn Tomasello. 10-K, filed 2023-03-23. Section “Director Compensation”. As printed: 59,920. View filing ↗
- Section 08, Priti Hegde. 10-K, filed 2023-03-23. Section “Director Compensation”. As printed: 54,920. View filing ↗
- Section 08, Axel Hoos. 10-K, filed 2023-03-23. Section “Director Compensation”. As printed: 54,920. View filing ↗
- Section 08, Ansbert Gadicke. 10-K, filed 2023-03-23. Section “Director Compensation”. As printed: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 332,000 + equity 0 + all other 0 = 332,000, summed across the director compensation table rows.
- TCR2 Therapeutics Inc (subject), Section 10b CEO total. 10-K, filed 2023-03-23. CEO total compensation as printed in TCR2 Therapeutics Inc's own proxy. As printed: 1,744,815. View filing ↗